A phase II clinical trial of cytembena. Clinical screening group of E.O.R.T.C.
In a phase II clinical (screening) trial, Cytembena has induced 20% objective regressions in uterus cervix carcinoma. This agent did not induce any myelosuppressive toxicity.
D000179:Acrylates / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*
D000179:Acrylates